[go: up one dir, main page]

WO2008001769A1 - Substance ou agent activant l'immunité intestinale, aliments, boissons et aliments pour animaux la ou le contenant - Google Patents

Substance ou agent activant l'immunité intestinale, aliments, boissons et aliments pour animaux la ou le contenant Download PDF

Info

Publication number
WO2008001769A1
WO2008001769A1 PCT/JP2007/062799 JP2007062799W WO2008001769A1 WO 2008001769 A1 WO2008001769 A1 WO 2008001769A1 JP 2007062799 W JP2007062799 W JP 2007062799W WO 2008001769 A1 WO2008001769 A1 WO 2008001769A1
Authority
WO
WIPO (PCT)
Prior art keywords
mannobiose
mannan
intestinal immunity
weight
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/062799
Other languages
English (en)
Japanese (ja)
Inventor
Futoshi Yokomizo
Masahisa Ibuki
Yoshinori Mine
Shigeru Katayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Oil Co Ltd (fka Fuji Oil Holdings Inc)
Original Assignee
Fuji Oil Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Oil Co Ltd filed Critical Fuji Oil Co Ltd
Priority to JP2008522588A priority Critical patent/JPWO2008001769A1/ja
Publication of WO2008001769A1 publication Critical patent/WO2008001769A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention is characterized in that the production of immunoglobulin A (IgA), an antibody important for intestinal immunity, is increased, characterized by comprising a plant mannan degradation product containing ⁇ _1,4_mannobiose as a main component.
  • IgA immunoglobulin A
  • the present invention relates to a composition having an intestinal immunity-stimulating action and a disease-preventing function caused by pathogenic bacteria and viruses, or a food or drink containing them.
  • the intestinal tract has been found to be the most important immune organ in the animal body.
  • Foods are carried by loca and enter the body. With food, pathogenic bacteria and viruses enter the body at the same time, and if they reach the intestine, they enter the body along with food ingredients. If you allow this invasion, it may lead to a life crisis. The intestinal tract that avoids this crisis is considered more immune functions.
  • the intestinal immune system distinguishes between safe and non-safe. Safe things are foods and useful microorganisms that are absorbed to help your health. However, even safe items exhibit some immune response, and in extreme cases allergies can occur. This is called oral tolerance, but I'm immune, but I'm immune. Care should be taken as it will disrupt the balance of oral tolerance. In other words, it is not all good to be said to be an immunostimulant, but it is important to use it after understanding the power and what is being activated. It is very dangerous academically to judge that everything is healthy with the word “immunity activation”.
  • IgA immune globulin A
  • This IgA is produced by the cells that make IgA in the Peyer's patch in the intestinal tract, and moves to the lower layer of the epithelial cells covering the intestinal lumen, and begins to make IgA.
  • This IgA enters the intestinal lumen and prevents the invasion of pathogenic bacteria and viruses. Therefore, This IgA is very important for disease prevention against these pathogenic bacteria and viruses, and if it has a composition or food power that can enhance IgA without compromising oral immune tolerance, It will greatly contribute to the food safety that has been said recently, and can be very effective.
  • this IgA is transported intracellularly and secreted to other mucosal surfaces, which can prevent not only resistance to pathogenic bacteria and viruses, but also the entry of allergens from the small intestine and nose. It is also important for prevention of onset.
  • JP-A-2005-75740 and JP-A-2005-97133 disclose that a mushroom extract power 3 ⁇ 4A production promoting function has been recently discussed.
  • JP-A-2005-330213 discloses that uridinoleic acid has its function. These are considered to have certain functions, and are required to be cheaper and easier to use.
  • Japanese Patent Application Laid-Open No. 2002-27922 proposes a simple hydrolyzed cobra meal or palm kernel meal as an immunostimulator with excellent safety and economy.
  • this patent document only shows that macrophage stimulation is equivalent to that of lipopolysaccharide (LPS), which is usually used as a control, in view of the production of interleukin-1 (IL-1) in immunization experiments.
  • LPS lipopolysaccharide
  • IL-1 interleukin-1
  • the proposed product itself stimulates the body's immune system, and there is concern about the problem of macrophage inflammation due to increased IL-1. There is also concern that these will place an extra burden on the body.
  • JP-A-2005-35896 proposes that ⁇ -type mannobiose, which can be removed relatively easily from the cell wall of yeast, has an effect of enhancing production of interleukin-12 (IL-12).
  • IL-12 interleukin-12
  • this IL-12 is a cell-mediated immune function that activates sputum cells and the like, and is not intended to promote the production of IgA.
  • vegetable ⁇ -type mannose oligosaccharide extracted from coffee is preferably useful as an immunostimulant, and stimulates the lymphocytes to promote their cell proliferation. It is exemplified.
  • the problems to be solved by the present invention are excellent in safety and economy, reliably promote IgA production without imposing a heavy load on the body, and prevent infection with external pathogenic bacteria and viruses.
  • Another object of the present invention is to provide an intestinal immunity stimulating composition, food and drink, and feed that can prevent allergies.
  • mannan-degrading enzymes act on mannan-containing natural products, particularly cobra meal and palm kernel meal, and simply hydrolyze them.
  • those containing at least 10% by weight or more of i3 1,4-mannobiose relative to mannan before decomposition are not affected by the site of IgA without the involvement of site force-in such as interleukin-6 (IL-6).
  • IL-6 interleukin-6
  • the present invention is based on a mannan-degrading product containing a mannan-degrading enzyme acting on a mannan-containing natural product and containing at least 10% by weight of / 3-1, 4_mannobiose based on mannan before decomposition. It is a composition having an immunostimulatory action characterized in that it relates to an immunostimulatory composition having an effect of promoting production of IgA, foods and drinks and feeds containing them.
  • ⁇ -1,4-mannobiose is composed of two D mannose molecules, 1, 4- It is a glycoside bond.
  • ⁇ -1,4 mannobiose can be obtained by, for example, a method of synthesizing from mannose or a method of decomposing ⁇ -1,4 mannan (hereinafter also simply referred to as mannan).
  • the method for decomposing ⁇ -1, 4 monomannan is more preferable in terms of raw material resources and reaction efficiency, and can provide / 3-1,4_mannobiose.
  • mannan-degrading enzyme is added to mannan-containing natural products such as coconut cake, palm kernel meal, cobra meal, gua gum, locust bean gum, etc. that are rich in mannan, or mannan extracted from these natural products.
  • the coconut cake is used as an edible solid product obtained by crushing the endosperm in coconut fruit into a slurry and solid-liquid decomposition.
  • Cobra meal generally refers to a residue obtained when palm oil is extracted from cobra obtained by drying core meat in coconut pulp by sun drying or hot air drying. In the present invention, the sun or hot air drying process is performed. Also includes oil extraction residue extracted without passing through.
  • the method for extracting coconut oil is not particularly limited, such as extraction using a solvent, etastruder or a combination of these.
  • Palm kernel meal is a residue obtained by extracting palm kernel oil from palm kernels, which are seeds of oil palm, and can also be extracted by solvent extraction, etastruder extraction or a combination thereof, but is particularly limited. It is not a thing. Among these, coconut cake is used for food, and is more preferably used in that the cost can be reduced by omitting the extraction and purification of mannobiose described later.
  • the decomposition of mannan must be enzymatic hydrolysis.
  • Typical examples of the hydrolysis method include acid decomposition.
  • hydrolysis by these methods causes acid modification of the resulting composition, and it is difficult to obtain the expected effect immediately.
  • mannanase is not particularly limited as long as it decomposes mannan and produces at least 10% by weight of / 3-1, 4_mannobiose to mannan before decomposition.
  • examples thereof include hemicellulases such as mannosidase.
  • commercially available preparations, culture solutions obtained by culturing bacterial cells, or those obtained after cell strength separation can be used.
  • hemicellulase GM “AMANO” (Amano Pharmaceutical Co., Ltd.) Sumiteam ACH (manufactured by Shin Nippon Chemical Industry Co., Ltd.), Singuchi Shin GM5 (Hankyu Bio Industry Co., Ltd.) and the like can be preferably used.
  • xylanase and cellulase those having the hydrolysis activity can be used.
  • cellulase Y-NC manufactured by Yakult Pharmaceutical Co., Ltd.
  • mannosidase (exo type) activity is low and mannanase (endo type) activity is high.
  • Hemicellulase GM “AMANO” (manufactured by Amano Pharmaceutical Co., Ltd.) and Sumiteam ACH (manufactured by Shin Nippon Chemical Industry Co., Ltd.) are responsible for the production of mannose. It is preferable in that it can be suppressed and a large amount of mannobiose can be generated.
  • the enzyme used in the present invention acts on mannan-containing natural products or extracted mannan as an enzyme solution dissolved or dispersed in water.
  • the amount of water added for water adjustment is preferably 50 to 10000 parts by weight with respect to 100 parts by weight of mannan, more preferably 50 to 1500 parts by weight.
  • the amount of the enzyme and the reaction time are at least 10% by weight of mannobiose produced with respect to mannan before decomposition, preferably 10 to 80% by weight of mannobiose produced by hydrolysis with respect to mannan before decomposition. %, So long as it is about%, a wet enzyme-treated product can be obtained under such conditions.
  • an enzyme having a high mannanase (endo type) activity usually also has a mannosidase (exo type) activity, if the enzyme reaction time is too long, mannobiose is decomposed and the amount of mannose increases. Therefore, the reaction time is preferably not longer than necessary.
  • These enzyme reaction conditions are appropriately set so that the amount of mannobiose produced is as large as possible.
  • beta-1, 4 if mannobiose is example preferred tool embodiment to set to include more than mannose, beta-1, 4 more preferable that the Ru der proportion force 60 weight 0/0 following mannose for mannobiose instrument 20 It is particularly preferred that it is not more than wt%.
  • palm kernel meal mannan content is approximately 36%)
  • the amount of mannobiose depends on the type, amount, and time of the enzyme used. Due to 100 parts by weight of raw material, 6 to 17 parts by weight can be generated.
  • the obtained decomposed product may be an aqueous solution composition as it is, preferably with a drying force.
  • the drying method is not particularly limited, and examples thereof include freeze-drying, spray drying, fluidized bed drying and the like, which are free from excipients such as dextrin.
  • ethanol is used to remove impurities from the obtained enzyme degradation product.
  • ethanol is preferable from the viewpoint of power safety that can include methanol, isopropanol, hexane, and the like. After removing impurities with ethanol, water extraction may be performed.
  • 1,4 mannobiose which is considered as a main component, is water-soluble
  • a concentration operation may be performed.
  • the drying method of the obtained water-soluble component is not particularly limited.
  • the aqueous composition may be used as it is without drying. Examples of the drying method include freeze-drying, spray drying and fluidized bed drying with an excipient such as dextrin.
  • the ⁇ -1, 4 mannobiose content is preferably hydrolyzed so as to be 10% by weight or more based on the weight of mannan before hydrolysis. There is no promotion of IgA production that is expected to be less than 10. IgA production promoting ability seen in the present invention Whether or not it is caused only by this ⁇ ⁇ 1, 4_mannobiose is not certain, but it is expected to act as at least a main component. However, since it is limited to coconut cake, cobra meal and palm kernel meal as a mannan-containing composition in order to obtain the expected effect of promoting IgA production, trace amounts of components present in these raw materials And ⁇ _ 1, 4_ mannobiose are considered to exhibit a unique effect.
  • the effect of the present invention can be obtained even when the amount of ⁇ _ 1, 4_ mannobiose is 100%, but it is economical to extract ⁇ _ 1 '4 _ mannobiose with high purity. Because it is burdensome and no synergistic effect with the estimated trace components can be expected, the content of ⁇ -1, 4 mannobiose is preferably 10% by weight or more and less than 90% by weight 15% by weight or more, 40% by weight Less than.
  • the intestinal immunity stimulating substance for promoting IgA production of the present invention may be appropriately formulated by a public method and used in the form of an intestinal immunity activator. It can be added to breads, confectionery, vitamins and other health foods and consumed as food and drink, and is not particularly limited. Similarly, it can be used as feed by adding it to fishery and terrestrial animal feeds.
  • Example 1 Example 2 Example 3 Copramysole raw material Palm kernel meal raw material Two pramille lees raw material arabinose 0.. 1 6 (%) 0.1 8 (%) 0.2 0 (%) Galactose 0 1 4 0. 1 3 0. 2 1 Guzore course 2.. 5 4 2. 3 1 1 0. 0 3 Mannose 1.. 3 8 1. 5 0 1 .5 4 Fructose 1 .. 3 8 1. 4 1 2. 7 1 ⁇ -1, 4-N-Nobiose 2 1,. 7 4 1 9. 8 0 3 6. 0 7
  • mice spleen cells were collected from 6-week-old BALB females (Charles River).
  • the collected spleen cells were loosened in RPMI1640 (Gibco BRL) containing 50 U / ml penicillin and 50 ⁇ g / ml streptomycin, and a cell suspension was obtained by centrifugation.
  • interleukin 6 which is important for IgA production
  • IFN- ⁇ interferon ⁇
  • IFN- ⁇ interferon ⁇
  • the mixture was made into a sandwich, reacted with a mixed enzyme solution of avidin and horseradish peroxidase, the color developed by the substrate TMB was measured with a microplate reader at 450 nm, and the content was calculated with a calibration curve.
  • ELISA kit OptEIA set, The content was measured by BD Bioscience).
  • Table 2 shows the results of the effect of promoting production of IgA, IgG, INF- ⁇ , and IL 6 in the examples.
  • the product of the present invention has the effect of stimulating the immune system to promote the production of IgA and IgG.
  • the production of INF- ⁇ and IL-6, which are site forces, is not promoted, indicating that it is a stimulant for a completely new immune system.
  • Table 3 shows the presence or absence of sputum cells or sputum cell activation promoting effects.
  • the present invention was found to have low T cell and B cell proliferation promoting effects. Therefore, the product of the present invention stimulates and proliferates the conventionally called T lymphocytes and B cells, and directly produces IgA and IgG, which does not prevent bacterial invasion. It turns out that it is a new one that promotes and protects against bacteria and the like. Industrial applicability
  • an antibody important for intestinal immunity characterized by comprising a plant mannan degradation product containing / 3_1,4_mannobiose as a main component. It has an intestinal tract immunostimulatory effect, and can be used for a composition having a disease-preventing function due to pathogenic bacteria or viruses, or a food or drink containing them.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne une substance ou un agent activant l'immunité intestinale qui contient un β-1,4-mannobiose.
PCT/JP2007/062799 2006-06-26 2007-06-26 Substance ou agent activant l'immunité intestinale, aliments, boissons et aliments pour animaux la ou le contenant Ceased WO2008001769A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008522588A JPWO2008001769A1 (ja) 2006-06-26 2007-06-26 腸管免疫賦活物質及び剤、並びにこれらを含有する飲食物及び飼料

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80575206P 2006-06-26 2006-06-26
US60/805,752 2006-06-26

Publications (1)

Publication Number Publication Date
WO2008001769A1 true WO2008001769A1 (fr) 2008-01-03

Family

ID=38845533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/062799 Ceased WO2008001769A1 (fr) 2006-06-26 2007-06-26 Substance ou agent activant l'immunité intestinale, aliments, boissons et aliments pour animaux la ou le contenant

Country Status (2)

Country Link
JP (1) JPWO2008001769A1 (fr)
WO (1) WO2008001769A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090179A4 (fr) * 2006-11-21 2012-01-04 Fuji Oil Co Ltd Composition alimentaire contenant un mano-oligosaccharide
WO2023114315A1 (fr) * 2021-12-17 2023-06-22 Quality Technology International, Inc. Composition et méthode de traitement des parasites chez un animal

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63209595A (ja) * 1987-02-27 1988-08-31 Towa Kasei Kogyo Kk β−１，４−マンノビオ−スの製造法
JPH02243697A (ja) * 1989-03-17 1990-09-27 Meiji Seika Kaisha Ltd オリゴ糖の製造法
JPH0838064A (ja) * 1994-07-26 1996-02-13 Meiji Seika Kaisha Ltd 有害細菌の感染を予防する飼料
JPH1118793A (ja) * 1997-07-03 1999-01-26 Unitika Ltd マンノビオースの製造方法
JP2001231591A (ja) * 2000-02-28 2001-08-28 Unitika Ltd マンノース及び／又はマンノオリゴ糖の製造方法
JP2002027922A (ja) * 2000-07-13 2002-01-29 Unitika Ltd 免疫賦活剤および飼料
JP2004159659A (ja) * 1999-09-14 2004-06-10 Ajinomoto General Foods Inc マンノオリゴ糖類を主成分とする組成物
WO2004048587A1 (fr) * 2002-11-26 2004-06-10 Itochu Feed Mills Co., Ltd. Composition contenant $g(b)-1,4-mannobiose
JP2006325587A (ja) * 2005-04-27 2006-12-07 Fuji Oil Co Ltd キャンピロバクター対策用組成物、飼料用添加剤及び飼料、並びにβ−１，４−マンノビオース含有組成物の使用方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63209595A (ja) * 1987-02-27 1988-08-31 Towa Kasei Kogyo Kk β−１，４−マンノビオ−スの製造法
JPH02243697A (ja) * 1989-03-17 1990-09-27 Meiji Seika Kaisha Ltd オリゴ糖の製造法
JPH0838064A (ja) * 1994-07-26 1996-02-13 Meiji Seika Kaisha Ltd 有害細菌の感染を予防する飼料
JPH1118793A (ja) * 1997-07-03 1999-01-26 Unitika Ltd マンノビオースの製造方法
JP2004159659A (ja) * 1999-09-14 2004-06-10 Ajinomoto General Foods Inc マンノオリゴ糖類を主成分とする組成物
JP2001231591A (ja) * 2000-02-28 2001-08-28 Unitika Ltd マンノース及び／又はマンノオリゴ糖の製造方法
JP2002027922A (ja) * 2000-07-13 2002-01-29 Unitika Ltd 免疫賦活剤および飼料
WO2004048587A1 (fr) * 2002-11-26 2004-06-10 Itochu Feed Mills Co., Ltd. Composition contenant $g(b)-1,4-mannobiose
JP2006325587A (ja) * 2005-04-27 2006-12-07 Fuji Oil Co Ltd キャンピロバクター対策用組成物、飼料用添加剤及び飼料、並びにβ−１，４−マンノビオース含有組成物の使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGUNOS A. ET AL.: "Effect of dietary beta1-4 mannobiose in the prevention of Salmonella enteritidis infection in broilers", BRITISH POULTRY SCIENCE, vol. 48, no. 3, 20 June 2007 (2007-06-20), pages 331 - 341, XP003020342 *
KUDOH K. ET AL.: "Effect of Indigestible Saccharides on b lymphocyte Response of Intestinal Mucosa and Cecal Fermentation in Rats", J. NUTR. SCI. VITAMINOL., vol. 44, no. 1, February 1998 (1998-02-01), pages 103 - 112, XP003020343 *
NAGURA T. ET AL.: "Eiyo to Men'ekikei no Seigyo Prebiotics to Men'eki", RINSHO EIYO, vol. 102, no. 5, 1 May 2003 (2003-05-01), pages 556 - 559, XP003020341 *
YAMADA K. ET AL.: "Dietary effect of guar gum and its partially hydrolyzed product on the lipid metabolism and immune fuction of Sprague-Dawley rats", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 63, no. 12, December 1999 (1999-12-01), pages 2163 - 2167, XP001056785 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090179A4 (fr) * 2006-11-21 2012-01-04 Fuji Oil Co Ltd Composition alimentaire contenant un mano-oligosaccharide
WO2023114315A1 (fr) * 2021-12-17 2023-06-22 Quality Technology International, Inc. Composition et méthode de traitement des parasites chez un animal

Also Published As

Publication number Publication date
JPWO2008001769A1 (ja) 2009-11-26

Similar Documents

Publication Publication Date Title
Maheshwari et al. Extraction and isolation of β‐glucan from grain sources—A review
US9320291B2 (en) Production of a saccharide composition comprising glucans and mannans by alkaline and acid hydrolysis of yeast cells
Vidanarachchi et al. Phytobiotics: alternatives to antibiotic growth promoters in monogastric animal feeds
US20100086647A1 (en) Feed or food products comprising fungal material
JP2011503161A (ja) 腸管の炎症性疾患を処置または予防する方法
DE60035604T2 (de) Heilmittel
CN112739417A (zh) 用于治疗与肠道微生物组的扰乱的组成或功能有关的病症的益生元
JP5740072B2 (ja) β−１，３−１，６−Ｄ−グルカンを用いたストレス緩和剤
JP4069253B2 (ja) 栄養添加物の製造方法、添加物、およびその使用
US20060178344A1 (en) Glucosamine and N-acetylglucosamine and methods of making the same fungal biomass
KR20100028258A (ko) 다시마의 발효에 의한 다량의 ｇａｂａ를 함유한 발효산물 및 이를 이용한 기능성 천연 발효조미료와 다시마 발효분말의 제조 방법
JP4307800B2 (ja) マンノオリゴ糖を含有する免疫賦活組成物
JP2010529980A (ja) 栄養組成物
WO2008001769A1 (fr) Substance ou agent activant l'immunité intestinale, aliments, boissons et aliments pour animaux la ou le contenant
JP6742981B2 (ja) 免疫調節剤及びその用途
JP5169827B2 (ja) 抗アレルギー組成物及び剤、並びにこれらを含有する飲食物及び飼料
JP4790996B2 (ja) 醸造副産物からの機能性素材の製造方法およびそれにより得られる機能性素材
US9351515B2 (en) Nutritional composition and methods of making and using same
KR101985644B1 (ko) 면역 증진제 및 이를 포함하는 면역 개선용 음식품 조성물
JP5186819B2 (ja) 抗炎症作用組成物及び剤、並びにこれらを含有する飲食物及び飼料
CN1245989C (zh) 免疫激活剂
CN117295502A (zh) 免疫刺激剂和葡聚糖组合物的制备方法
KR20200083815A (ko) 보리 발효추출물을 이용한 알레르기성 질환의 예방, 개선 및 치료용 조성물의 제조 방법
JPH07121867B2 (ja) 肝機能活性化剤
JP2025145799A (ja) エガセラ属細菌／ビロフィラ属細菌の菌数抑制用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07767605

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008522588

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07767605

Country of ref document: EP

Kind code of ref document: A1